Literature DB >> 18435759

Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold.

Per-Ake Nygren1.   

Abstract

In recent years, classical antibody-based affinity reagents have been challenged by novel types of binding proteins developed by combinatorial protein engineering principles. One of these classes of binding proteins of non-Ig origin are the so-called affibody binding proteins, functionally selected from libraries of a small (6 kDa), non-cysteine three-helix bundle domain used as a scaffold. During the first 10 years since they were first described, high-affinity affibody binding proteins have been selected towards a large number of targets for use in a variety of applications, such as bioseparation, diagnostics, functional inhibition, viral targeting and in vivo tumor imaging/therapy. The small size offers the possibility to produce functional affibody binding proteins also by chemical synthesis production routes, which has been found to be advantageous for the site-specific introduction of various labels and radionuclide chelators.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18435759     DOI: 10.1111/j.1742-4658.2008.06438.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  77 in total

1.  An intein-mediated site-specific click conjugation strategy for improved tumor targeting of nanoparticle systems.

Authors:  Drew R Elias; Zhiliang Cheng; Andrew Tsourkas
Journal:  Small       Date:  2010-11-05       Impact factor: 13.281

2.  Structure prediction and validation of an affibody engineered for cell-specific nucleic acid targeting.

Authors:  Vijaya Gopal; Kunchur Guruprasad
Journal:  Syst Synth Biol       Date:  2011-02-17

3.  Engineered lactic acid bacterium Lactococcus lactis capable of binding antibodies and tumor necrosis factor alpha.

Authors:  Matjaz Ravnikar; Borut Strukelj; Natasa Obermajer; Mojca Lunder; Ales Berlec
Journal:  Appl Environ Microbiol       Date:  2010-08-27       Impact factor: 4.792

Review 4.  Research and development of next generation of antibody-based therapeutics.

Authors:  Jing Li; Zhenping Zhu
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

5.  Synthetic and natural consensus design for engineering charge within an affibody targeting epidermal growth factor receptor.

Authors:  Brett A Case; Benjamin J Hackel
Journal:  Biotechnol Bioeng       Date:  2016-02-04       Impact factor: 4.530

Review 6.  Using in-vivo fluorescence imaging in personalized cancer diagnostics and therapy, an image and treat paradigm.

Authors:  Y Ardeshirpour; V Chernomordik; J Capala; M Hassan; R Zielinsky; G Griffiths; S Achilefu; P Smith; A Gandjbakhche
Journal:  Technol Cancer Res Treat       Date:  2011-12

7.  A modular IgG-scFv bispecific antibody topology.

Authors:  Kelly Davis Orcutt; Margaret E Ackerman; Maryelise Cieslewicz; Emmanuel Quiroz; Adrian L Slusarczyk; John V Frangioni; K Dane Wittrup
Journal:  Protein Eng Des Sel       Date:  2009-12-17       Impact factor: 1.650

8.  (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.

Authors:  Anna Orlova; Thuy A Tran; Torun Ekblad; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-22       Impact factor: 9.236

9.  HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging.

Authors:  Ilya Lyakhov; Rafal Zielinski; Monika Kuban; Gabriela Kramer-Marek; Robert Fisher; Oleg Chertov; Lakshman Bindu; Jacek Capala
Journal:  Chembiochem       Date:  2010-02-15       Impact factor: 3.164

10.  Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.

Authors:  Vladimir Tolmachev; Daniel Rosik; Helena Wållberg; Anna Sjöberg; Mattias Sandström; Monika Hansson; Anders Wennborg; Anna Orlova
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.